Glycyrrhetinic acid-modified chitosan nanoparticles enhanced the effect of 5-fuorouracil in murine liver cancer model via regulatory T-cells

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 1287-1299

  Mingrong, Cheng ^a,b   Xu, Hongzhi ^c   Wang, Yong ^d   Chen, Houxiang ^e   He, Bing ^c   Gao, Xiaoyan ^b   Li, Yingchun ^b   Han, Jiang ^a   Zhang, Zhiping ^a  

^a Department of general surgery ^*  (China)

^b Pudong New Area Zhoupu Hospital   (China)

^c FUDAN UNIVERSITY   (China)

^d WUHAN UNIVERSITY OF TECHNOLOGY   (China)

^e Zhejiang huafon Fiber research institute   (China)

Author keywords

5 fuorouracil; Glycyrrhetinic acid; Hepatic carcinoma; Regulatory T cells; Targeted therapy

Indexed keywords

CHITOSAN; FLUOROURACIL; GAMMA INTERFERON; GLYCYRRHETINIC ACID; INTERLEUKIN 2; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; LIVER CANCER; LIVER CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PARTICLE SIZE; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; REGULATORY T LYMPHOCYTE; SCANNING ELECTRON MICROSCOPY; STEADY STATE; SURVIVAL TIME; SUSTAINED RELEASE FORMULATION; TIMED DRUG RELEASE; TUMOR VOLUME;

5-FLUOROURACIL; GLYCYRRHETINIC ACID; HEPATIC CARCINOMA; REGULATORY T CELLS; TARGETED THERAPY;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL PROLIFERATION; CHITOSAN; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; FEMALE; FLUOROURACIL; GLYCYRRHETINIC ACID; INTERFERON-GAMMA; INTERLEUKIN-2; KILLER CELLS, NATURAL; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NANOPARTICLES; PARTICLE SIZE; SURVIVAL RATE; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TIME FACTORS;

EID: 84886643149     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S52809     Document Type: Article

References (40)

1. Oh IH, Min HS, Li L, et al. Cancer cell-specific photoactivity of pheo-phorbide a-glycol chitosan nanoparticles for photodynamic therapy in tumor-bearing mice. Biomaterials. 2013;34(27):6545-6563.
2. Hamman JH. Chitosan based polyelectrolyte complexes as potential carrier materials in drug delivery systems. Mar Drugs. 2010;8(4): 1305-1322.
3. Arulmozhi V, Pandian K, Mirunalini S. Ellagic acid encapsulated chi-tosan nanoparticles for drug delivery system in human oral cancer cell line (KB). Colloids Surf B Biointerfaces. 2013;110:313-320.
4. Javid A, Ahmadian S, Saboury AA, Kalantar SM, Rezaei-Zarchi S. Chitosan-coated superparamagnetic iron oxide nanoparticles for Doxo-rubicin delivery: synthesis and anticancer effect against human ovarian cancer cells. Chem Biol Drug Des. 2013;82(3):296-305.
5. Huang X, Wang Y, Cai J P, et al. Sustained release of 5-fuorouracil from chitosan nanoparticles surface modified intra ocular lens to prevent posterior capsule opacification: an in vitro and in vivo study. J Ocul Pharmacol Ther. 2013;29(2):208-215.
6. Xu J, Ma L, Liu Y, Xu F, Nie J, Ma G. Design and characterization of antitumor drug paclitaxel-loaded chitosan nanoparticles by W/O emulsions. Int J Biol Macromol. 2012;50(2):438-443.
7. Yan S, Zhu J, Wang Z, Yin J, Zheng Y, Chen X. Layer-by-layer assembly of poly(L-glutamic acid)/chitosan microcapsules for high loading and sustained release of 5-fuorouracil. Eur J Pharm Biopharm. 2011;78(3):336-345.
8. Park JH, Saravanakumar G, Kim K, Kwon IC. Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv Drug Deliv Rev. 2010;62(1):28-41.
9. Yu JM, Li YJ, Qiu LY, Jin Y. Polymeric nanoparticles of cholesterol-modified glycol chitosan for doxorubicin delivery: preparation and in-vitro and in-vivo characterization. J Pharm Pharmacol. 2009;61(6): 713-719.
10. He ZY, Zheng X, Wu XH, et al. Development of glycyrrhetinic acid-modified stealth cationic liposomes for gene delivery. Int J Pharm. 2010;397(1-2):147-154.
11. Tian Q, Zhang CN, Wang XH, et al. Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery. Biomaterials. 2010;31(17):4748-4756.
12. Huang W, Wang W, Wang P, et al. Glycyrrhetinic acid-modified poly(ethylene glycol)-b-poly(gamma-benzyl l-glutamate) micelles for liver targeting therapy. Acta Biomater. 2010;6(10):3927-3935.
13. Toriumi F, Kubota T, Saikawa Y, et al. Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fuorouracil in advanced gastric carcinoma. Anticancer Res. 2004;24(4):2455-2463.
14. Johnson KR, Wang L, Miller MC, Willigham MC, Fan W. 5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells. Clin Cancer Res. 1997;3(10):1739-1745.
15. Fang JY, Liu PF, Huang CM. Decreasing systemic toxicity via transdermal delivery of anticancer drugs. Curr Drug Metab. 2008;9: 592-597.
16. Chen Y, Wang X, Ya n Z, Wang J, Luo J, Liu Q. Hepatic arterial infusion with irinotecan, oxaliplatin, and foxuridine plus systemic chemotherapy as frst-line treatment of unresectable liver metastases from colorectal cancer. Onkologie. 2012;35(9):480-484.
17. Takahashi Y, Yamashita K, Endo Y, Sasaki T, Mai M. Oral administration of uracil-tegafur (UFT) inhibits liver micrometastasis of human colon cancer in an orthotopic nude mouse model and its early detection system. Surg Today. 2004;34(10):855-859.
18. Wu T, Zhang L, Xu K, et al. Immunosuppressive drugs on inducing Ag-specific CD4(+)CD25(+)Foxp3(+) Treg cells during immune response in vivo. Transpl Immunol. 2012;27(1):30-38.
19. Li J, Feng G, Liu J, et al. Renal cell carcinoma may evade the immune system by converting CD4+Foxp3- T cells into CD4+CD25+Foxp3+ regulatory T cells: Role of tumor COX-2-derived PGE2. Mol Med Rep. 2010;3(6):959-963.
20. Sellitto A, Galizia G, De Fanis U, et al. Behavior of circulating CD4+CD25+Foxp3+ regulatory T cells in colon cancer patients undergoing surgery. J Clin Immunol. 2011;31(6):1095-1104.
21. Mao C, Wang S, Jiang Q, et al. Increased CD4CD25+FOXP3+ regulatory T Cells in cancer patients from conversion of CD4+CD25-T cells through tumor-derived factors. Onkologie. 2008;31(5): 243-248.
22. Bamias A, Koutsoukou V, Terpos E, et al. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecol Oncol. 2008;108(2):421-427.
23. Shi YX, Zhang XS, Liu DG, Li YQ, Guan ZZ, Jiang WQ. CD4+CD25+T regulatory cells in peripheral blood of B-NHL patients with or without chemotherapy. Ai Zheng. 2004;23(5):597-601. Chinese [with English abstract].
24. Jeong HG, Yo u HJ, Park SJ, et al. Hepatoprotective effects of 18beta-glycyrrhetinic acid on carbon tetrachloride-induced liver injury: inhibition of cytochrome P450 2E1 expression. Pharmacol Res. 2002;46(3): 221-227.
25. Lallemand B, Gelbcke M, Dubois J, Prévost M, Jabin I, Kiss R. Structure-activity relationship analyses of glycyrrhetinic acid derivatives as anticancer agents. Mini Rev Med Chem. 2011;11(10):881-887.
26. Tian Q, Wang XH, Wang W, Zhang CN, Wang P, Yuan Z. Self-assembly and liver targeting of sulfated chitosan nanoparticles functionalized with glycyrrhetinic acid. Nanomedicine. 2012;8(6):870-879.
27. Huang W, Wang W, Wang P, et al. Glycyrrhetinic acid-functionalized degradable micelles as liver-targeted drug carrier. J Mater Sci Mater Med. 2011;22(4):853-863.
28. Negishi M, Irie A, Nagata N, Ichikawa A. Specific binding of glycyr-rhetinic acid to the rat liver membrane. Biochim Biophys Acta. 1991; 1066(1):77-82.
29. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol. 2004;56(7):827-840.
30. Zhu L, Ma J, Jia N, Zhao Y, Shen H. Chitosan-coated magnetic nano-particles as carriers of 5-fuorouracil: preparation, characterization and cytotoxicity studies. Colloids Surf B Biointerfaces. 2009;68(1):1-6.
31. Ligabue A, Marverti G, Liebl U, Myllykallio H. Transcriptional activation and cell cycle block are the keys for 5-fuorouracil induced up-regulation of human thymidylate synthase expression. PLoS One. 2012;7(10):e47318.
32. Nabeya Y, Suzuki T, Furuya A, et al. Calpain regulates thymidylate synthase-5-fuoro-dUMP complex levels associated with response to 5-fuorouracil in gastric cancer cells. Cancer Sci. 2011;102(8): 1509-1515.
33. Cheng M, He B, Wan T, et al. 5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model. PLoS One. 2012;7(10):e47115.
34. Hibasami H, Iwase H, Yoshioka K, Takahashi H. Glycyrrhetic acid (a metabolic substance and aglycon of glycyrrhizin) induces apoptosis in human hepatoma, promyelotic leukemia and stomach cancer cells. Int J Mol Med. 2006;17(2):215-219.
35. Ramstead AG, Schepetkin IA, Quinn MT, Jutila MA. Oenothein B, a cyclic dimeric ellagitannin isolated from Epilobium angustifolium, enhances IFNγ production by lymphocytes. PLoS One. 2012;7(11): e50546.
36. Ramstead AG, Jutila MA. Complex role of γδ T-cell-derived cytokines and growth factors in cancer. J Interferon Cytokine Res. 2012;32(12): 563-569.
37. Zanon RG, Cartarozzi L P, Victório SC, et al. Interferon (IFN) beta treatment induces major histocompatibility complex (MHC) class I expression in the spinal cord and enhances axonal growth and motor function recovery following sciatic nerve crush in mice. Neuropathol Appl Neurobiol. 2010;36(6):515-534.
38. Zhao MF, Qu XJ, Qu JL, et al. The role of E3 ubiquitin ligase Cbl proteins in interleukin-2-induced Jurkat T-cell activation. Biomed Res Int. 2013;2013:430861.
39. Whiteside TL. What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol. 2012;22(4):327-334.
40. Bergmann C, Wild CA, Narwan M, Lotf R, Lang S, Brandau S. Human tumor-induced and naturally occurring Treg cells differentially affect NK cells activated by either IL-2 or target cells. Eur J Immunol. 2011;41(12):3564-3573.